Efficacy of a β-adrenergic receptor antagonist, propranolol, in preventing ischaemic ventricular fibrillation: Dependence on heart rate and ischaemia duration

Cardiovascular Research

Volumn 37, Issue 3, 1998, Pages 646-655

  Aupetit, Jean F ^a   Frassati, Dominique ^b   Bui Xuan, Bernard ^b   Freysz, Marc ^b   Faucon, Georges ^b   Timour, Quadiri ^b  

^a CENTRE HOSPITALIER SAINT JOSEPH SAINT LUC   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Adrenergic receptor antagonists; Adrenergic receptors; Myocardial ischaemia; Pig; Propranolol; Ventricular fibrillation

Indexed keywords

BETA ADRENERGIC RECEPTOR; ISOPRENALINE; PROPRANOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; HEART MUSCLE ISCHEMIA; HEART RATE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; SINUS NODE; SWINE;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; CARDIAC PACING, ARTIFICIAL; ELECTROPHYSIOLOGY; FEMALE; HEART RATE; ISOPROTERENOL; MALE; MYOCARDIAL ISCHEMIA; PROPRANOLOL; SWINE; TIME FACTORS; VENTRICULAR FIBRILLATION;

EID: 0032029364     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00304-0     Document Type: Article

References (34)

1. [1] Wilhelmsen C, Wilhelmsen L, Vedin JA. Reduction of sudden death after myocardial infarction by treatment with alprenolol. Lancet 1974;2:1157-1161.
2. [2] Beta-blocker Heart Attack Trial (BHAT) Research Group, A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. J Am Med Assoc 1982;247:1707-1714.
3. [3] Capone R, Friedman L, Byington R. The effect of propranolol on mortality in patients following acute myocardial infarction with complex ventricular arrhythmias (for the BHAT Study Group). Circulation 1983;68(Suppl. III):294-302.
4. [4] ISIS-1 Collaborative Group, Randomized trial of intravenous atenolol among 16027 cases of suspected myocardial infarction. Lancet 1986;2:57-65.
5. [5] Puddu PE, Jouve R, Langlet F. Prevention of postischaemic ventricular fibrillation by long-term beta adrenoceptor blockade with acebutolol in the anaesthetised dog. Cardiovasc Res 1986;20:721-726.
6. [6] Rehnqvist N. Prevention of sudden death by beta-blockade. Cardiovasc Drugs Ther 1990;4:675-680.
7. [7] Anderson JL, Rodier HE, Green LS. Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol 1983;51:1196-1202.
8. [8] Bergey JL, Wendt RL, Nocella K, McCallum JD. Acute coronary artery occlusion-reperfusion arrhythmias in pigs: antiarrhythmic and antifibrillatory evaluation of verapamil, nifedipine, prenylamine and propranolol. Eur J Pharmacol 1984;97:95-103.
9. [9] Nanas JN, Kralios A. Relative effects of propranolol and timolol on ventricular fibrillation threshold and hemodynamics in the dog. Am Heart J 1986;111:1094-1100.
10. [10] Muller CA, Opie LH, Peisach M, Pineda CA, Hamm CW, Thandroyen FT. Critical role of dose in protection by propranolol against ventricular fibrillation in a pig model of acute myocardial ischemia. J Cardiovasc Pharmacol 1989;13:192-197.
11. [11] Verdouw PD, van Bremen RH, Verkeste CM, van der Giessen WJ. Antiarrhythmic action and protection of ischaemic myocardium after beta-blockade with bevantolol. Eur J Pharmacol 1985;111:377-380.
12. [12] Knopf H, McDonald FM, Bischoff A, Hirche Hj, Addicks K. Effect of propranolol on early postischemia arrhythmias and noradrenaline and potassium release of ischemic myocardium in anesthetized pigs. J Cardiovasc Pharmacol 1988;12(Suppl. I):S41-S47.
13. [13] Aupetit JF, Timour Q, Loufoua-Moundanga J, Omar S, Chevrel G, Faucon G. Vulnerability to ventricular fibrillation related to ischaemia. Comparison of the acute effects of β-blockers and calcium antagonists. Arch Int Pharmacodyn 1994;327:25-39.
14. [14] Aupetit JF, Timour Q, Loufoua-Moundanga J, Barral-Cadière L, Lopez M, Freysz M, Faucon G. Profibrillatory effects of lidocaine in the acutely ischemic porcine heart. J Cardiovasc Pharmacol 1995;25:810-816.
15. [15] Aupetit JF, Freysz M, Faucon G, Loufoua-Moundanga J, Timour Q. Change of a beneficial effect into an untoward effect by ischaemia: effect of quinidine-like drugs on vulnerability to ventricular fibrillation. Environm Tox Pharmacol 1996;2:1-7.
16. [16] Aupetit JF, Timour Q, Chevrel G, Loufoua-Moundanga J, Omar S, Faucon G. Attenuation of the ischaemia-induced fall of electrical ventricular fibrillation threshold by a calcium antagonist, diltiazem. Naunyn-Schmiedeberg's Arch Pharmacol 1993;348:509-514.
17. [17] Bui-Xuan B, Aupetit JF, Freysz M, Loufoua-Moundanga J, Faucon G, Timour Q. Disappearance with ischaemic depolarization of the antifibrillatory activity in a sodium channel blocker and appearance in a calcium channel blocker. Arch Int Pharmacodyn 1996;331:246-262.
18. [18] Bui-Xuan B, Aupetit JF, Freysz M, Loufoua-Moundanga J, Faucon G, Timour Q. Cardiac β-adrenoceptor activation and ventricular fibrillation under normal and ischaemic conditions. Cardiovasc Res 1996;32:1056-1063.
19. [19] Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989;69:1049-1169.
20. [20] James RGG, Arnold JMO, Allen JD, Pantridge JF, Shanks RG. The effects of heart rate, myocardial ischemia and vagal stimulation on the threshold for ventricular fibrillation. Circulation 1977;55:311-317.
21. [21] Clusin WT, Buchbinder M, Ellis AK, Kernoff RS, Giacomini JC, Harrison DC. Reduction of ischemic depolarization by the calcium channel blocker diltiazem. Circ Res 1984;54:10-20.
22. [22] Kloner RA, Braunwald E. Effects of calcium antagonists on infarcting myocardium. Am J Cardiol 1987;59:84B-94B.
23. [23] Timour Q, Bui-Xuan B, Faucon G, Aupetit JF. Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia. Cardiovasc Drugs Ther 1996;10:447-454.
24. [24] Boyett MR, Jewell BR. Analysis of the effects of changes in rate and rhythm upon electrical activity of the heart. Prog Biophys Mol Biol 1980;36:1-52.
25. [25] Lang J, Timour Chah Q, Charve P, Aupetit JF, El Chebly M, Faucon G. Role of calcium in the rate-dependent depression of atrioventricular nodal conduction in the dog heart under vagal influence. Int J Cardiol 1987;15:65-76.
26. [26] Franz MR, Schaefer J, Schöttler W, Seed WA, Noble MM. Electrical and mechanical restitution of the human heart at different rates of stimulation. Circ Res 1983;53:815-822.
27. [27] Boyett MR, Fedida D. A simple model of ion concentration changes in the heart during repetitive activity. J Physiol (Lond) 1983;342:52P-53P.
28. + activity in swine. Circulation 1980;61:768-778.
29. [29] Lyons CJ, Burgess MJ, Abildskov JA. Effects of acute hyperkalemia on cardiac excitability. Am Heart J 1977;94:755-763.
30. [30] Vassalle M, Barnabei O. Norepinephrine and potassium fluxes in cardiac Purkinje fibers. Arch ges Physiol 1971;322:287-298.
31. [31] Skinner JE, Lie JT, Entman HL. Modification of ventricular fibrillation latency following coronary artery occlusion in the conscious pig. The effect of psychological stress and beta-adrenergic blockade. Circulation 1975;51:656-667.
32. [32] Sutherland EW, Robison GA. The role of cyclic-3′5′ AMP in response to catecholamines and other hormones. Pharmacol Rev 1966;18:145-161.
33. [33] Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term myocardial infarction intervention trials. Am J Cardiol 1986;57:43F-49F.
34. [34] Kralios AC, Tsagaris TJ, Kuida H. Effect of coronary vasodilation on ventricular fibrillation threshold of vasodilators and perfusion conditions. Am Heart J 1983;105:580-590.